Opendata, web and dolomites

SENCAN SIGNED

Senescence therapy for cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SENCAN" data sheet

The following table provides information about the project.

Coordinator
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS 

Organization address
address: PLESMANLAAN 121
city: AMSTERDAM
postcode: 1066 CX
website: www.nki.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙478˙750 €
 EC max contribution 2˙478˙750 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS NL (AMSTERDAM) coordinator 2˙478˙750.00

Map

 Project objective

Systemic treatment of advanced cancers is hampered by the development of drug resistance. To prevent resistance, my laboratory has in the past used functional genetic screens to discover several “synthetic lethal” drug combination therapies, which has resulted in 8 clinical trials to date, including one global phase 3 study. In this program, I propose a new approach to the treatment of cancer, which is not based on combinations of drugs, but rather on the sequential treatment with drugs. In a first treatment step, cells will not only be induced to stop dividing, but they will at the same time acquire a major new vulnerability that is subsequently targeted with a second drug that selectively kills cells having the newly acquired vulnerability. To accomplish this, we will take advantage of recent observations that the cellular senescence response is not only a property of primary cells, but can also be triggered in advanced cancers. Such senescent cells have dramatic changes in gene expression, chromatin structure and metabolism that we will exploit for their selective eradication. Using chemical compound libraries and loss-of-function genetic screens in cancer cells harboring a reporter gene that is activated selectively in senescent cells, we will search for genes and compounds that induce senescence in cancer cells. This will lead to the identification of compounds and/or signaling pathways whose inhibition induces senescence in cancer cells. We will also use chemical compound screens to find tools to selectively kill senescent cancer cells. We will use the targets and compounds identified in this program to test the in vivo efficacy of this “one-two punch” consecutive therapy approach: the first to induce senescence in cancer cells, the subsequent therapy to eradicate the senescent cells. We present here preliminary data that the concept of sequential drug treatment can be effective, which serves as an important proof of concept for the strategy proposed here.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

MOCHA (2019)

Understanding and leveraging ‘moments of change’ for pro-environmental behaviour shifts

Read More  

Mu-MASS (2019)

Muonium Laser Spectroscopy

Read More  

EXTREME (2020)

The Epistemology and Ethics of Fundamentalism

Read More